• Earlier in June 2026, Neurocrine Biosciences reported new post-hoc KINECT 4 trial data and clinician-reported real-world findings showing that INGREZZA (valbenazine) produced clinically meaningful reductions in tardive dyskinesia movements and functional gains across varied adult patient groups, including those with intellectual and developmental disabilities.
• Together, these results highlight INGREZZA’s breadth of evidence in complex, often underserved populations and underscore its positioning as a VMAT2 inhibitor with remission data, hepatic dosing flexibility and once-daily, sprinkle-capable formulations.
• We’ll now examine how this broader, real-world efficacy signal for INGREZZA may influence Neurocrine Biosciences’ investment narrative and growth assumptions.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine Biosciences, you have to believe INGREZZA can keep anchoring the business while CRENESSITY and the broader CNS pipeline steadily add depth. The new KINECT 4 and real-world data modestly reinforce INGREZZA’s clinical profile and could support volume-focused growth, but they do not materially change the near term focus on payer pressure, Medicare contracting and pricing as the most important catalyst and risk.

Among recent updates, the April 2026 real world analysis comparing INGREZZA with AUSTEDO XR is particularly relevant. Higher treatment persistence and lower switching in this head to head claims review speak directly to INGREZZA’s competitive position, which underpins both the upside case tied to continued franchise expansion and the downside risk of overreliance on a single product in an increasingly scrutinized reimbursement setting.

Yet behind this strong clinical story, investors should still be aware that growing Medicare and payer scrutiny could...

Neurocrine Biosciences' narrative projects $5.1 billion revenue and $1.5 billion earnings by 2029. This requires 18.0% yearly revenue growth and an earnings increase of about $831 million from $668.6 million today.

Uncover how Neurocrine Biosciences' forecasts yield a $192.88 fair value, a 21% upside to its current price.

Exploring Other Perspectives

By contrast, the most optimistic analysts were already assuming revenue could reach about US$5.8 billion and earnings US$1.8 billion, so this fresh INGREZZA data may either reinforce their belief in segment expansion or prompt a rethink, reminding you that reasonable views on Neurocrine’s future can differ widely.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $192.88!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.